Condition: Alcohol Use Disorder (AUD) · Post Traumatic Stress Disorder (PTSD) · Sponsor: Pharmacotherapies for Alcohol and Substance Use Disorders Alliance
The overall objective of the proposed study is to determine if Dexmedetomidine HCl (BXCL501) is safe for treatment of alcohol use disorder (AUD) with comorbid posttraumatic stress disorder (PTSD) in an outpatient setting and also shows potential signals of efficacy thereby supporting the conduct of later phase clinical trials.
This description comes directly from the study's public registry record.
Ismene Petrakis, MD · (203) 932-5711 · ismene.petrakis@yale.edu
Jenelle Newcomb, BA · (203) 932-5711 · jenelle.leblanc@yale.edu
Always discuss trial participation with your own doctor first.
| VA Connecticut Healthcare System | West Haven, Connecticut, United States | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06335407